StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/307% above fair value
$28.76−0.92 (-3.10%)

Close on Nov 19, 2026Market cap $1.72BP/E –Yield –

Agios Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Agios Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$459.02M. For fiscal 2025 it was -$472.13M. The highest annual figure on record is -$16.63M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$472.13M–
FY2024Dec 31, 2024-$425.74M–
FY2023Dec 31, 2023-$391.49M–
FY2022Dec 31, 2022-$389.05M–
FY2021Dec 31, 2021-$378.42M–
FY2020Dec 31, 2020-$335.92M–
FY2019Dec 31, 2019-$316.27M–
FY2018Dec 31, 2018-$362.48M–
FY2017Dec 31, 2017-$320.79M–
FY2016Dec 31, 2016-$200.99M–
FY2015Dec 31, 2015-$118.70M–
FY2014Dec 31, 2014-$54.13M–
FY2013Dec 31, 2013-$38.88M–
FY2012Dec 31, 2012-$23.00M–
FY2011Dec 31, 2011-$16.63M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$110.55M–
Q1 FY2026Mar 31, 2026-$110.03M–
Q4 FY2025Dec 31, 2025-$121.58M–
Q3 FY2025Sep 30, 2025-$116.87M–
Q2 FY2025Jun 30, 2025-$127.06M–
Q1 FY2025Mar 31, 2025-$106.63M–
Q4 FY2024Dec 31, 2024-$125.04M–
Q3 FY2024Sep 30, 2024-$102.81M–
Q2 FY2024Jun 30, 2024-$105.82M–
Q1 FY2024Mar 31, 2024-$92.07M–
Q4 FY2023Dec 31, 2023-$106.28M–
Q3 FY2023Sep 30, 2023-$100.90M–
Q2 FY2023Jun 30, 2023-$93.70M–
Q1 FY2023Mar 31, 2023-$90.61M–
Q4 FY2022Dec 31, 2022-$99.17M–
Q3 FY2022Sep 30, 2022-$91.09M–
Q2 FY2022Jun 30, 2022-$97.64M–
Q1 FY2022Mar 31, 2022-$101.15M–
Q4 FY2021Dec 31, 2021-$104.83M–
Q3 FY2021Sep 30, 2021-$91.15M–
Q2 FY2021Jun 30, 2021-$91.22M–
Q1 FY2021Mar 31, 2021-$91.22M–
Q4 FY2020Dec 31, 2020-$92.43M–
Q3 FY2020Sep 30, 2020-$80.29M–
Q2 FY2020Jun 30, 2020-$83.26M–
Q1 FY2020Mar 31, 2020-$87.03M–
Q4 FY2019Dec 31, 2019-$105.93M–
Q3 FY2019Sep 30, 2019-$109.06M–
Q2 FY2019Jun 30, 2019-$113.86M–
Q1 FY2019Mar 31, 2019-$97.48M–
Q4 FY2018Dec 31, 2018-$96.36M–
Q3 FY2018Sep 30, 2018-$99.16M–
Q2 FY2018Jun 30, 2018-$72.95M–
Q1 FY2018Mar 31, 2018-$94.01M–
Q4 FY2017Dec 31, 2017-$90.13M–
Q3 FY2017Sep 30, 2017-$79.02M–
Q2 FY2017Jun 30, 2017-$84.60M–
Q1 FY2017Mar 31, 2017-$67.05M–
Q4 FY2016Dec 31, 2016-$57.41M–
Q3 FY2016Sep 30, 2016-$63.51M–

More Agios Pharmaceuticals figures

See a number that looks wrong?